The DOI matches its Crossref record; 149 of the 149 references it cites were found in a registry or an index.
Chemotherapy Side-Effects: Not All DNA Damage Is Equal
Open accessAbstract
Recent advances have increased survival rates of children and adults suffering from cancer thanks to effective anti-cancer therapy, such as chemotherapy. However, during treatment and later in life they are frequently confronted with the severe negative side-effects of their life-saving treatment. The occurrence of numerous features of accelerated aging, seriously affecting quality of life, has now become one of the most pressing problems associated with (pediatric) cancer treatment. Chemotherapies frequently target and damage the DNA, causing mutations or genome instability, a major hallmark of both cancer and aging. However, there are numerous types of chemotherapeutic drugs that are genotoxic and interfere with DNA metabolism in different ways, each with their own biodistribution, kinetics, and biological fate. Depending on the type of DNA lesion produced (e.g., interference with DNA replication or RNA transcription), the organ or cell type inflicted (e.g., cell cycle or differentiation status, metabolic state, activity of clearance and detoxification mechanisms, the cellular condition or micro-environment), and the degree of exposure, outcomes of cancer treatment can largely differ. These considerations provide a conceptual framework in which different classes of chemotherapeutics contribute to the development of toxicities and accelerated aging of different organ systems. Here, we summarize frequently observed side-effects in (pediatric) ex-cancer patients and discuss which types of DNA damage might be responsible.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21590 · Cited by 20,444
Instability and decay of the primary structure of DNA
Lindahl, T. (1993) · Nature · doi:10.1038/362709a0 · Cited by 5,679
Cisplatin in cancer therapy: Molecular mechanisms of action
Dasari, S., & Bernard Tchounwou, P. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.025 · Cited by 5,537
5-Fluorouracil: mechanisms of action and clinical strategies
Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1074 · Cited by 5,332
The resurgence of platinum-based cancer chemotherapy
Kelland, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2167 · Cited by 4,717
Yang, W., Soares, J., Greninger, P., Edelman, E. J., Lightfoot, H., Forbes, S., Bindal, N., Beare, D., Smith, J. A., Thompson, I. R., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1111 · Cited by 4,051
Genome maintenance mechanisms for preventing cancer
Hoeijmakers, J. H. J. (2001) · Nature · doi:10.1038/35077232 · Cited by 3,939
Childhood and adolescent cancer statistics, 2014
Ward, E., DeSantis, C., Robbins, A., Kohler, B., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21219 · Cited by 2,412
Topoisomerase I inhibitors: camptothecins and beyond
Pommier, Y. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1977 · Cited by 2,277
Hoeijmakers, J. H. J. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804615 · Cited by 2,239
Research works printed but not linked: 22
- Schulpen, 2021, Significant improvement in survival of advanced stage childhood and young adolescent cancer in the Netherlands since the 1990s, Eur. J. Cancer, 157, 81, 10.1016/j.ejca.2021.08.001 · doi:10.1016/j.ejca.2021.08.001
- Caglar, 2002, Cumulative prior dose of cisplatin as a cause of the nephrotoxicity of high-dose chemotherapy followed by autologous stem-cell transplantation, Nephrol. Dial. Transplant., 17, 1931, 10.1093/ndt/17.11.1931 · doi:10.1093/ndt/17.11.1931
- Fukasawa, 2014, Anti-cancer agent-induced nephrotoxicity, Anticancer Agents Med. Chem., 14, 921, 10.2174/1871520614666140127105809 · doi:10.2174/1871520614666140127105809
- Grigorian, 2014, Hepatotoxicity secondary to chemotherapy, J. Clin. Transl. Hepatol., 2, 95
- Madeddu, 2016, Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy, J. Cardiovasc. Med., 17, S12, 10.2459/JCM.0000000000000376 · doi:10.2459/jcm.0000000000000376
- Elliott, 2006, Pathogenesis of cardiotoxicity induced by anthracyclines, Semin. Oncol., 33, 2, 10.1053/j.seminoncol.2006.04.020 · doi:10.1053/j.seminoncol.2006.04.020
- Tamamyan, 2016, Chemotherapy induced thrombocytopenia in pediatric oncology, Crit. Rev. Oncol. Hematol., 99, 299, 10.1016/j.critrevonc.2016.01.005 · doi:10.1016/j.critrevonc.2016.01.005
- Lokich, 1976, Managing chemotherapy-induced bone marrow suppression in cancer, Hosp. Pract., 11, 61, 10.1080/21548331.1976.11706980 · doi:10.1080/21548331.1976.11706980
- Germanas, 2002, Alkylating agents, Dermatol. Ther., 15, 317, 10.1046/j.1529-8019.2002.01540.x · doi:10.1046/j.1529-8019.2002.01540.x
- Waweru, 2007, Chemotherapy induced myelosuppression, East Afr. Med. J., 84, 8
- Corral, 2016, Cerebellar toxicity due to cytarabine: A series of 4 cases, Neurol. A, 7, 491
- Ferrazzi, 1991, DNA damage and cytotoxicity induced by metabolites of anthracycline antibiotics, doxorubicin and idarubicin, Cancer Commun., 3, 173, 10.3727/095535491820873308 · doi:10.3727/095535491820873308
- Sawyer, 2013, Anthracyclines and Heart Failure, N. Engl. J. Med., 368, 1154, 10.1056/NEJMcibr1214975 · doi:10.1056/nejmcibr1214975
- Bachur, 1982, Nuclear catalyzed antibiotic free radical formation, Cancer Res., 42, 1078
- 2007, Molecular basis of anthracycline-induced cardiotoxicity, Heart Metab., 35, 1
- Lowe, 1980, Adriamycin and daunomycin dose-dependent effects upon contractions of isolated rat myocytes, Cancer Chemother. Pharmacol., 5, 61, 10.1007/BF00578564 · doi:10.1007/bf00578564
- Bow, 1998, Infection risk and cancer chemotherapy: The impact of the chemotherapeutic regimen in patients with lymphoma and solid tissue malignancies, J. Antimicrob. Chemother., 41, 1, 10.1093/jac/41.suppl_4.1 · doi:10.1093/jac/41.suppl_4.1
- Bhatnagar, 2005, Pancytopenia in children: Etiological profile, J. Trop. Pediatr., 51, 236, 10.1093/tropej/fmi010 · doi:10.1093/tropej/fmi010
- Landier, 2016, Ototoxicity and cancer therapy, Cancer, 122, 1647, 10.1002/cncr.29779 · doi:10.1002/cncr.29779
- Cappaert, 2005, Acceleration of cisplatin ototoxicity by perilymphatic application of 4-methylthiobenzoic acid, Hear. Res., 203, 80, 10.1016/j.heares.2004.10.012 · doi:10.1016/j.heares.2004.10.012
- Levi, 2015, Anti-Müllerian Hormone Is a Marker for Chemotherapy-Induced Testicular Toxicity, Endocrinology, 156, 3818, 10.1210/en.2015-1310 · doi:10.1210/en.2015-1310
- Meijer, 2021, Recommendations for Age-Appropriate Testing, Timing, and Frequency of Audiologic Monitoring During Childhood Cancer Treatment: An International Society of Paediatric Oncology Supportive Care Consensus Report, JAMA Oncol., 7, 1550, 10.1001/jamaoncol.2021.2697 · doi:10.1001/jamaoncol.2021.2697
Cited by
Biosynthesis of Gold and Silver Nanoparticles Using Phytochemical Compounds
Zuhrotun, A., Oktaviani, D. J., & Hasanah, A. N. (2023) · Molecules · doi:10.3390/molecules28073240 · Cited by 281
Overcoming Barriers in Cancer Biology Research: Current Limitations and Solutions
(2025) · doi:10.3390/cancers17132102 · Cited by 44
MDM2 inhibition in the treatment of glioblastoma: From concept to clinical investigation
Pellot Ortiz, K. I., Rechberger, J. S., Nonnenbroich, L. F., Daniels, D. J., & Sarkaria, J. N. (2023) · Biomedicines · doi:10.3390/biomedicines11071879 · Cited by 30
Li, X., Huang, Z., Liao, Z., Liu, A., & Huo, S. (2023) · Nanoscale · doi:10.1039/d2nr06621a · Cited by 13
Metadata
- Authors
- van den Boogaard, W. M. C., Komninos, D. S. J., & Vermeij, W. P.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2022-01-26
- Volume
- 14
- Issue
- 3
- Pages
- 627
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W4210395111
- Cited by
- 458
- References
- 149
- FWCI
- 31.22
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- Oncode Institute (-)
- ADPS Longevity Research Award (-)
- Regiodeal Foodvalley (162135)
- BBoL (NWO-ENW) (737.016.015)
- ZonMW Memorabel (733050810)
- EJP-RD (RD20-113)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chemotherapy Side-Effects: Not All DNA Damage Is Equal. https://app.cochat.ai/papers/10.3390/cancers14030627
- The paper
- van den Boogaard, W. M. C., Komninos, D. S. J., & Vermeij, W. P. (2022). Chemotherapy Side-Effects: Not All DNA Damage Is Equal. Cancers. https://doi.org/10.3390/cancers14030627
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
